REGENXBIO FY2025 EPS Forecast Reduced by Chardan Capital

REGENXBIO Inc. (NASDAQ:RGNX) – Investment analysts at Chardan Capital reduced their FY2025 EPS estimates for REGENXBIO in a research report issued to clients and investors on Wednesday, May 14th. Chardan Capital analyst D. Gataulin now anticipates that the biotechnology company will post earnings per share of ($3.25) for the year, down from their prior forecast of ($3.03). Chardan Capital has a “Buy” rating and a $52.00 price target on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.41 by ($0.29). REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $89.01 million for the quarter, compared to analysts’ expectations of $105.35 million.

Other equities research analysts have also issued research reports about the company. Morgan Stanley lifted their price target on REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, March 14th. Raymond James began coverage on REGENXBIO in a research note on Friday, February 7th. They issued an “outperform” rating and a $27.00 target price for the company. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. Royal Bank of Canada restated an “outperform” rating and issued a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st. Finally, Leerink Partners set a $24.00 price objective on shares of REGENXBIO in a research note on Tuesday, March 18th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, REGENXBIO presently has an average rating of “Moderate Buy” and an average target price of $31.63.

REGENXBIO Stock Up 2.9%

RGNX opened at $8.89 on Monday. The business’s fifty day simple moving average is $7.54 and its 200 day simple moving average is $7.97. REGENXBIO has a 52 week low of $5.04 and a 52 week high of $16.25. The stock has a market cap of $445.92 million, a PE ratio of -1.77 and a beta of 1.11.

Insider Buying and Selling at REGENXBIO

In other news, Director Kenneth T. Mills sold 20,602 shares of the company’s stock in a transaction dated Monday, May 12th. The shares were sold at an average price of $7.91, for a total transaction of $162,961.82. Following the completion of the transaction, the director now directly owns 475,103 shares of the company’s stock, valued at approximately $3,758,064.73. This represents a 4.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 12.79% of the company’s stock.

Institutional Trading of REGENXBIO

Several large investors have recently modified their holdings of RGNX. Assenagon Asset Management S.A. raised its position in REGENXBIO by 53.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after purchasing an additional 296,700 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in shares of REGENXBIO by 8.6% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 164,729 shares of the biotechnology company’s stock valued at $1,273,000 after buying an additional 13,014 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in shares of REGENXBIO during the fourth quarter valued at approximately $1,062,000. Raymond James Financial Inc. bought a new position in shares of REGENXBIO during the fourth quarter valued at approximately $568,000. Finally, Teacher Retirement System of Texas lifted its stake in REGENXBIO by 19.9% in the fourth quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock worth $97,000 after acquiring an additional 2,088 shares during the period. 88.08% of the stock is owned by institutional investors.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.